This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (63)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

L. Michael Cobo, MD; Douglas J. Coster, FRCS, FRACS; Noel S. C. Rice, MD, FRCS; Barrie R. Jones, FRCS, FRCP, FRACS

Arch Ophthalmol. 1980;98(10):1755-1759.

Abstract
• One hundred thirty-two penetrating keratoplasties (91 patients) for herpetic keratoplasty were reviewed retrospectively. The overall survival rate of clear keratoplasties to two years was 64% and to five years was 62%. The significant prognostic factors were preoperative ocular inflammatory status and degree of corneal vascularization. The two-year survival rate of a clear keratoplasty was 69% where eyes were inflamed at the time of surgery, compared with 44% in actively inflamed eyes. Allograft rejection, the major cause of a clouded herpetic keratoplasty, increased in frequency with increasing corneal vascularization. Antiviral cover was not used with routine postoperative steroids or with steroid intensive therapy for rejection. Epithelial herpetic recurrences occurred in 32% of eyes undergoing allograft rejection within four months of initiation of treatment for rejection. This is compared with otherwise uncomplicated keratoplasties where the epithelial recurrence rate was 6% at four months, on high-dose postoperative corticosteroid therapy without antiviral cover.

Author Affiliations
From the Institute of Ophthalmology, Department of Clinical Ophthalmology and Pathology, University of London, Moorfields Eye Hospital. Dr Cobo is now at Duke University Eye Center, Durham, NC.

Footnotes
Accepted for publication April 12, 1980.

Reprint requests to Duke University Eye Center, PO Box 3802, Durham, NC 27710 (Dr Cobo).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Boston Keratoprosthesis in Herpetic Keratitis
Khan et al.
Arch Ophthalmol 2007;125:745-749.
ABSTRACT | FULL TEXT  

Tacrolimus immunosuppression in high-risk corneal grafts
Joseph et al.
Br J Ophthalmol 2007;91:51-55.
ABSTRACT | FULL TEXT  

Penetrating keratoplasty: outcomes from a corneal unit compared to national data
Beckingsale et al.
Br J Ophthalmol 2006;90:728-731.
ABSTRACT | FULL TEXT  

Penetrating keratoplasty: indications over a 10 year period
Al-Yousuf et al.
Br J Ophthalmol 2004;88:998-1001.
ABSTRACT | FULL TEXT  

The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin
Halberstadt et al.
Br J Ophthalmol 2002;86:646-652.
ABSTRACT | FULL TEXT  

Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis
Tambasco et al.
Arch Ophthalmol 1999;117:445-449.
ABSTRACT | FULL TEXT  

Corneal transplantation for herpes simplex keratitis
LARKIN
Br J Ophthalmol 1998;82:107-108.
FULL TEXT  

Antiviral Therapy After Penetrating Keratoplasty for Herpes Simplex Keratitis
Moyes et al.
Arch Ophthalmol 1994;112:601-607.
ABSTRACT  

Recurrent Herpes Simplex Keratitis With Concurrent Epithelial and Stromal Involvement: Immunohistochemical and Ultrastructural Observations
Holbach et al.
Arch Ophthalmol 1991;109:692-695.
ABSTRACT  

Oral Acyclovir Reduces the Incidence of Recurrent Herpes Simplex Keratitis in Rabbits After Penetrating Keratoplasty
Beyer et al.
Arch Ophthalmol 1989;107:1200-1205.
ABSTRACT